911227-48-0

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 490-78-8 2,5-Dihydroxyacetophenone 

Downstream Products

• 936648-32-7 tert-butyl 6-methoxy-4-oxospiro[chroman-2,4′-piperidine]-1′-carboxylate 
• 1354927-46-0 C₂₆H₃₃NO₃ 

Relevant academic research and scientific papers

Synthesis and evaluation of a new series of 1′-cyclobutyl-6-(4- piperidyloxy)spiro[benzopyran-2,4′-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists

A novel class of 1′-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2, 4′-piperidine] derivatives with low nanomolar affinity for the human and rat histamine-3 receptors (H3Rs) are described. The spirobenzopyran piperidine ether analogs demonstrated excellent H3R affinity and selectivity against histamine receptor subtypes (H1R, H2R, and H4R), were stable in liver microsomes, and had selectivity against CYP P450 enzymes. Compounds 10, 13, 15, and 16 demonstrated high H 3R affinity, in vitro liver microsomal stability, selectivity against CYP isoforms, moreover, these ether analogs exhibited acceptable iv pharmacokinetic (PK) properties but had poor oral exposure in rat.

Spirocyclic sulfonamides with carbonic anhydrase inhibitory and anti-neuropathic pain activity

A novel series of 4-oxo-spirochromane bearing primary sulfonamide group were synthetized as Carbonic Anhydrase inhibitors (CAIs) and tested for their management of neuropathic pain. Indeed, CAs have been recently validated as novel therapeutic targets in neuropathic pain. All compounds, here reported, showed strong activity against hCA II and hCA VII with KI values in the low or sub-nanomolar range. Two compounds (6d and 6l) showed good neuropathic pain attenuating effects and longer duration than drug reference acetazolamide in an animal model of oxaliplatin induced neuropathy.

Synthesis and evaluation of 4-alkoxy-[1′-cyclobutyl-spiro(3,4- dihydrobenzopyran-2,4′-piperidine)] analogues as histamine-3 receptor antagonists

A novel class of 4-alkoxy-[1′-cyclobutyl-spiro(3,4-dihydrobenzopyran- 2,4′-piperidine)] analogues were designed and synthesized as H 3R antagonists. Structure-activity relationship identified sulfone 27 with excellent H3R affinities

SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS

The present invention provides compounds of Formula (I): their use as H3 antagonists/inverse agonists, processes for their preparation, and pharmaceuticals compositions thereof.

SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS

The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating mammals suffering from the condition of being overweight.

Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: Discovery of N,N-diethyl-4-(5-hydroxyspiro-[chromene-2, 4′-piperidine]-4-yl)benzamide (ADL5859)

Selective δ opioid receptor agonists are promising potential therapeutic agents for the treatment of various types of pain conditions. A spirocyclic derivative was identified as a promising hit through screening. Subsequent lead optimization identified compound 20 (ADL5859) as a potent, selective, and orally bioavailable δ agonist. Compound 20 was selected as a clinical candidate for the treatment of pain.

SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE

Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.

SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE

Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and